● Recruiting

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

Condition: Advanced Malignant Solid Tumours · Sponsor: Sinocelltech Ltd.

PhasePhase 1/Phase 2

Planned participants441

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

This description comes directly from the study's public registry record.

Talk to the study team

xiaoman zhang · +86-10-58628288-9134 · xiaoman_zhang@sinocelltech.com

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06600022